OOIR: Observatory of International Research

Papers

(The TQCC of Expert Opinion on Investigational Drugs is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Navafenterol for chronic obstructive pulmonary disease therapy	101
Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?	80
Experimental drugs for supraventricular tachycardia: an analysis of early phase clinical trials	76
Novel experimental and early investigational drugs for the treatment of bipolar disorder	74
Lipid metabolism and the targeting of angiopoietin-like 3: Experimental drugs under development	73
Investigational drugs for HIV: trends, opportunities and key players	69
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions	62
Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?	58
Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia	55
Targeting leukemia inhibitory factor in pancreatic adenocarcinoma	52
The effect of a single escalating dose of long-acting recombinant human follicle-stimulating hormone Fc fusion protein (KN015) on healthy, pituitary-suppressed women: first-in-human and randomized stu	50
A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a nov	49
Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities	49
Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus	42
The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials	41
Progress in the treatment of anal cancer: an overview of the latest investigational drugs	40
Odevixibat: an investigational inhibitor of the ileal bile acid transporter (IBAT) for the treatment of biliary atresia	40
Therapies in preclinical and in early clinical development for the treatment of urinary tract infections: from pathogens to therapies	36
From bench to bedside - is there a role of IL-17 drugs in rheumatoid arthritis?	32
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy	32
Novel preclinical developments of the primary sclerosing cholangitis treatment landscape	31
A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects	31
Lessons learned from early-stage clinical trials for diabetic nephropathy	30
Investigational follicle-stimulating hormone receptor agonists for male infertility therapy	26
Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights	26

Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia	26
Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies	25
The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022	25
Bruton tyrosine kinase inhibitors: can they be optimized for the treatment of neuroinflammatory disorders?	22
Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development	22
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects	21
Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities	21
Experimental drugs for the prevention or treatment of sensorineural hearing loss	20
Investigational gene expression inhibitors for the treatment of idiopathic pulmonary fibrosis	20
Experimental drugs in randomized controlled trials for long-COVID: what’s in the pipeline? A systematic and critical review	20
Metabolic dysfunction and insulin sensitizers in acute and chronic disease	20
Investigational drugs for the treatment of olfactory dysfunction	19
Theranostic strategies in sarcoma: preliminary clinical evidence	19
AXS-05: an investigational treatment for Alzheimer’s disease-associated agitation	19
Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development	19
Pancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years	18
Fibroblast growth factor therapies in biliary tract cancers: current and future state	18
RNAi therapeutics for diseases involving protein aggregation: fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease	17
Ongoing phase 2 agents for multiple sclerosis: could we break the phase 3 trial deadlock?	17
MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma	17
Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials	17
Inhibition of KIT for chronic urticaria: a status update on drugs in early clinical development	16
Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension	15
Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity	15
First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa	15
SGLT2 inhibitors: an evidence-based update on cardiovascular implications	14
New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology	14
Recent progress in tyrosine kinase 2 inhibitors for atopic dermatitis	14
Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 partici	14
Therapeutic challenges at the preclinical level for targeted drug development for Opisthorchis viverrini-associated cholangiocarcinoma	14
New investigational drugs for steroid-refractory acute graft-versus-host disease: a review of the literature	14
Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers	14
Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer	14
Therapies in preclinical and clinical development for Angelman syndrome	14
Application of engineered antibodies (scFvs and nanobodies) targeting pathological protein aggregates in Alzheimer’s disease	13
Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development	13
Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver	13
Anti-diabetic drugs and NASH: from current options to promising perspectives	12
Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer	12
Investigational drugs for ischemic stroke: what’s in the clinical development pipeline for acute phase and prevention?	12
Foreword: hepatocellular carcinoma: emerging treatments, drug targets, and fundamental knowledge gaps	12
Low-dose aspirin for early COVID-19: does the early bird catch the worm?	12
An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension	11
Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)	11
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies	11
Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases	11
Therapeutic potential of cannabidiol (CBD) in the treatment of cardiovascular diseases	11
JAK inhibitors for rheumatoid arthritis	10
Combination therapies in clinical trials for renal cell carcinoma: how could they impact future treatments?	10
Emerging treatment landscape for Guillain-Barré Syndrome (GBS): what’s new?	10

Experimental drugs for fallopian cancer: promising agents in the clinical trials and key stumbling blocks for researchers	10
Bomedemstat as an investigative treatment for myeloproliferative neoplasms	10
Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials	10
Atezolizumab: an investigational agent for the treatment of biliary tract cancer	10
Immunotherapeutic strategies for treating opioid use disorder and overdose	10
Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis	10
Interleukin antagonists for atopic dermatitis: a new era of therapy	10
Psoriasis: a focus on upcoming oral formulations	10
Investigational drugs for the treatment of scleroderma: what’s new?	10
Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?	9
Investigational drugs in clinical trials for macular degeneration	9
T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development	9
Investigational topical anticholinergics in clinical development for the treatment of hyperhidrosis	9
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond	9
Neuropathic pain management: a focused review of current treatments and novel data from main ongoing clinical trials	9
Collocation of metformin and dipeptidyl peptidase-4 inhibitor is associated with increased risk of diabetes-related vascular dementia: A single hospital study in Northern Taiwan	9
Epigenetic regulation of radioresistance: insights from preclinical and clinical studies	9
Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma	9
Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia	8
JAK inhibitors in crohn’s disease: ready to go?	8
Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review	8
The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy	8
Experimental drugs for Friedrich’s ataxia: progress and setbacks in clinical trials	8
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects	8
The role of phosphodiesterase 9A inhibitors in heart failure	8
Investigational bispecific antibodies for the treatment of rheumatoid arthritis	8
‘Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research’	8
Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects	8
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents	8
Targeting diarrhea-predominant irritable bowel syndrome: hopes or hypes?	8
Taletrectinib for the treatment of ROS-1 positive non-small cell lung cancer: a drug evaluation of phase I and II data	8